Ker Yu
Discovery Oncology and Discovery Medicinal Chemistry
Wyeth Research
Pearl River
New York 10965
USA
Name/email consistency: high
- Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J.E., Zhang, W.G., Mahoney, R., Gaydos, C., Tardio, L., Kim, S.K., Conant, R., Curran, K., Kaplan, J., Verheijen, J., Ayral-Kaloustian, S., Mansour, T.S., Abraham, R.T., Zask, A., Gibbons, J.J. Cancer Res. (2010)
- Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Yu, K., Toral-Barza, L., Shi, C., Zhang, W.G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D.J., Cole, D.C., Ellingboe, J., Ayral-Kaloustian, S., Mansour, T.S., Gibbons, J.J., Abraham, R.T., Nowak, P., Zask, A. Cancer Res. (2009)
- Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Yu, K., Toral-Barza, L., Shi, C., Zhang, W.G., Zask, A. Cancer Biol. Ther. (2008)
- PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Yu, K., Lucas, J., Zhu, T., Zask, A., Gaydos, C., Toral-Barza, L., Gu, J., Li, F., Chaudhary, I., Cai, P., Lotvin, J., Petersen, R., Ruppen, M., Fawzi, M., Ayral-Kaloustian, S., Skotnicki, J., Mansour, T., Frost, P., Gibbons, J. Cancer Biol. Ther. (2005)
